Alzheimer’s Disease Study Questions Glucosamine Safety

Key Summary

• • New research published in Nature Metabolism suggests that abnormal brain glycosylation may contribute to Alzheimer’s disease progression.
  • Glucosamine supplementation worsened memory deficits and behavioral outcomes in Alzheimer’s mouse models.
  • Genetic suppression of glycosylation pathways improved cognitive performance in mice.
  • Analysis of dementia patient health records linked glucosamine use with a 25% higher mortality risk and increased progression from mild cognitive impairment to dementia.
  • Researchers emphasize that human findings are observational and call for randomized clinical trials to assess the safety of glucosamine in patients with dementia.
  • For More Updates in Neurology, Check out & Register for the American Neurology Summit 2026

Glucosamine and Alzheimer’s Disease: Study Links Supplement to Cognitive Decline

Alzheimer’s disease researchers are raising new questions about the safety of glucosamine supplementation after a major study identified a potential link between increased brain glycosylation and worsening cognitive outcomes. Published in Nature Metabolism, the study combines advanced brain tissue analysis, animal experiments, and real-world patient data to investigate how glycan metabolism may influence neurodegeneration.

How Does Glycosylation Affect Alzheimer’s Disease?

Alzheimer’s disease remains one of the most challenging neurodegenerative disorders, characterized by progressive cognitive decline, neuronal loss, synaptic dysfunction, and neuroinflammation. While abnormal glucose metabolism has long been associated with disease progression, researchers are now focusing on glycosylation as another critical metabolic pathway.

Glycosylation is the biological process through which glycans, or complex carbohydrate molecules, attach to proteins and influence their stability and function. In the brain, proper glycosylation supports neuronal communication, synaptic plasticity, and immune signaling. However, abnormal glycosylation has been associated with amyloid-beta accumulation, tau aggregation, and neuroinflammatory responses.

Using spatial multiomics, isotope-tracing technologies, and post-mortem human brain tissue analysis, investigators identified significantly elevated N-glycan levels in both gray and white matter regions affected by Alzheimer’s disease. Notably, hyperglycosylation increased alongside disease severity, suggesting a potential role in disease progression.

Hyperglycosylation May Be a New Alzheimer’s Disease Biomarker

The study found that increased glycan production was not merely a byproduct of neurodegeneration. When researchers genetically reduced the activity of glycosylation-related enzymes in Alzheimer’s mouse models, cognitive performance improved. These findings suggest that glycan dysregulation may directly contribute to memory impairment.

Can Glucosamine Worsen Cognitive Decline?

To evaluate the impact of dietary glucosamine, researchers administered the supplement to genetically modified 5xFAD mice, a widely used Alzheimer’s disease model. The intervention resulted in increased protein glycosylation and significantly worsened behavioral and memory deficits.

Interestingly, the cognitive decline occurred without measurable changes in amyloid plaques, tau pathology, or reactive astrocyte activity. This finding indicates that glycosylation may affect cognition through mechanisms beyond traditional Alzheimer’s disease hallmarks.

Glucosamine Supplementation and Dementia Risk

Investigators expanded their analysis to electronic health records of patients diagnosed with Alzheimer’s disease and related dementias (ADRD) or mild cognitive impairment (MCI). Approximately 8% of patients had documented glucosamine use.

After adjusting for age, sex, and demographic factors, glucosamine use was associated with a 25% increase in mortality risk over 10 years among patients with established dementia. Researchers also observed a 25% higher rate of progression from mild cognitive impairment to ADRD among glucosamine users.

Because the analysis was retrospective, the findings do not establish causation. Over-the-counter supplement use may be underreported, and residual confounding factors cannot be excluded.

What Are the Clinical Implications for Healthcare Professionals?

The findings highlight glycosylation as a potential therapeutic target in Alzheimer’s disease and underscore the need for greater scrutiny of common dietary supplements in vulnerable patient populations.

For More Updates in Neurology, Check out & Register for the American Neurology Summit 2026

For neurologists, geriatricians, primary care physicians, and dementia care teams, the study reinforces the importance of reviewing supplement use during patient assessments. While glucosamine remains widely used for joint health, its impact on patients with established dementia requires further investigation through well-designed, double-blind clinical trials.

Until prospective clinical evidence becomes available, healthcare professionals may consider discussing the emerging data with patients and caregivers when evaluating supplement use in dementia management.

Source:

Nature